H.C. Wainwright downgraded Shattuck Labs to Neutral from Buy and removing the firm’s price target based on the company moving from a clinical stage to preclinical stage upon discontinuation of SL-172154 for heme-onc and introduction of SL-325. The firm will look to potentially reassess its valuation based on factors such as clarity around pipeline development for the new lead assets SL-325 and SL-425, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts
- Shattuck Labs provides pipeline and financial update
- Shattuck Labs price target lowered to $8 from $9 at Citi
- Shattuck Labs: Cash equivalents and investments will be sufficient into 2026
- Shattuck Labs reports Q2 EPS (42c), consensus (41c)